Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
Meningiomas are common intracranial tumors categorized as Grades I-III per the current WHO guidelines. A small percentage of meningiomas are Grades II and III, which are likely to recur after initial treatment. Grade III meningiomas are considered to be malignant and warrant aggressive management. If surgery and radiation fail to produce lasting remission, effective treatment options for patients with progressive anaplastic meningiomas are elusive. The authors present the case of a patient with a meningioma that gradually progressed from Grade I to Grade III over 12 years despite repeated surgery and radiation therapy. The patient has been in remission for over 3 years following octreotide therapy.
Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan;
Richard
R
Rammo
Rosalind Franklin University Medical School, North Chicago, Illinois; and.
Adam
A
Rock
Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan;
Andrea
A
Transou
Division of Anatomic Pathology, Mayo Clinic, Rochester, Minnesota.
Aditya
A
Raghunathan
Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan;
Jack
J
Rock
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008579:Meningioma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D009364:Neoplasm Recurrence, Local; D015282:Octreotide / Q000627:therapeutic use*; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D015282:Octreotide
PBS = phosphate-buffered saline; SST = somatostatin receptor; intracranial; meningioma; octreotide; oncology